Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
Department of Internal Medicine, Dong-Eui Medical Center, Busan, South Korea.
J Gastroenterol Hepatol. 2023 Sep;38(9):1485-1495. doi: 10.1111/jgh.16202. Epub 2023 May 2.
Biologic-era data regarding the direct cost and healthcare utilization of inflammatory bowel disease at the population level are limited, especially in Asia. Thus, we aimed to investigate the nationwide prevalence, direct cost, and healthcare utilization of inflammatory bowel disease in Korea in a recent 10-year period.
Using the Korean National Health Insurance claim data from 2008 to 2017, we investigated all prescription medications and their associated direct costs, hospitalizations, and outpatient visits. We also estimated the nationwide prevalence of inflammatory bowel disease using population census data.
The estimated inflammatory bowel disease prevalence significantly increased from 108.8/100 000 in 2008 to 140.4/100 000 in 2017. The overall annual costs for inflammatory bowel disease and the healthcare cost per capita increased from $24.5 million (in US dollars) to $105.1 million and from $458.4 to $1456.6 million, respectively (both P < 0.001). Whereas the ratio of outpatient costs increased from 35.3% to 69.4%, that of outpatient days remained steady. The total annual medication cost and proportion rose from $13.3 million to $76.8 million and from 54.2% to 73.3%, respectively, mainly due to the increasing antitumor necrosis factor cost, from $1.5 million to $49.3 million (from 11.1% to 64.1% of the total annual drug cost and from 6.3% to 46.9% of the total annual cost).
We observed increasing trends in the prevalence, direct costs, and healthcare utilization of inflammatory bowel disease in Korea in recent years. The attributable cost was mainly driven by rising expenditures on antitumor necrosis factor medications.
生物时代有关炎症性肠病在人群水平上的直接成本和医疗保健利用的数据有限，特别是在亚洲。因此，我们旨在调查韩国最近 10 年来炎症性肠病的全国患病率、直接成本和医疗保健利用情况。
使用 2008 年至 2017 年的韩国国家健康保险索赔数据，我们调查了所有处方药物及其相关的直接费用、住院和门诊就诊情况。我们还使用人口普查数据估算了炎症性肠病的全国患病率。
炎症性肠病的估计患病率从 2008 年的 108.8/100000 显著增加到 2017 年的 140.4/100000。炎症性肠病的总年度费用和人均医疗保健费用从 2450 万美元（以美元计）增加到 1.051 亿美元和从 4584 万美元增加到 1.4566 亿美元（均 P < 0.001）。虽然门诊费用的比例从 35.3%增加到 69.4%，但门诊天数保持稳定。总年度药物费用和比例从 1330 万美元增加到 7680 万美元和从 54.2%增加到 73.3%，主要是由于抗 TNF 药物费用的增加，从 150 万美元增加到 4930 万美元（从总年度药物费用的 11.1%增加到 64.1%和从总年度费用的 6.3%增加到 46.9%）。
近年来，我们观察到韩国炎症性肠病的患病率、直接成本和医疗保健利用呈上升趋势。归因成本主要由抗 TNF 药物支出的增加驱动。
